Vinod Khosla Says AI Is Creating a ‘Hyperabundance’ of New Drugs, but Testing Is Still ‘18th-Century’

Venture capitalist Vinod Khosla argues that while artificial intelligence is rapidly increasing the volume of potential new medicines, current clinical trial processes remain inefficient and outdated. He suggests that the pace of drug discovery has outstripped the capacity of traditional testing methods, creating a bottleneck that delays the arrival of new treatments to patients.